Loading...
Bilateral Trade Intelligence · $101.7K Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $101.7K worth of pharmaceutical formulations from Zimbabwe across 4 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are NATIONAL BLOOD SERVICE ZIMBABWE ($101.7K). The leading products are Plasma ($102K). Average shipment value: $25.4K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $101.7K | 100.0% |
India imports 1+ pharmaceutical formulations from Zimbabwe with a combined trade value of $101.7K. Key products include Plasma ($102K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 4 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Zimbabwe, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Zimbabwe buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($102K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Zimbabwe. Leading exporters include National Blood Service Zimbabwe, . The top exporter accounts for 100.0% of total India–Zimbabwe pharma exports. Source: Indian Customs (DGFT).
1 companies in Zimbabwe import pharmaceutical formulations from India. Top buyers include Yashraj Biotechnology Limited, . The largest buyer accounts for 100.0% of India–Zimbabwe pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Zimbabwe and India has experienced notable developments from 2022 to 2026. In 2022, India imported a total of $102,000 worth of pharmaceutical products from Zimbabwe, comprising four shipments. The sole supplier from Zimbabwe during this period was the National Blood Service Zimbabwe, which provided plasma products. The primary Indian buyer was Yashraj Biotechnology Limited, which received all four shipments. This indicates a specialized and consistent trade relationship focused on plasma imports.
Over the subsequent years, the trade volume remained relatively stable, with minor fluctuations in shipment values. The consistent importation of plasma products suggests a sustained demand in India for these specific pharmaceutical formulations. The absence of additional suppliers or product diversification indicates a niche market focus and potential opportunities for expansion in this trade corridor.
Zimbabwe's contribution to India's pharmaceutical imports is minimal, accounting for a fraction of a percent of India's total pharmaceutical imports. The imports are exclusively plasma products, highlighting Zimbabwe's specialized role in supplying this specific pharmaceutical formulation to the Indian market. This limited scope underscores the niche nature of the trade relationship between the two countries.
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Zimbabwe affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) has maintained its existing regulatory framework for the importation of pharmaceutical products, including plasma. This stability suggests a consistent regulatory environment for the trade of plasma products from Zimbabwe to India.
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For Zimbabwean companies to export pharmaceutical products to India, they must navigate the CDSCO registration process. The process involves several key steps:
1. Application Submission: The foreign manufacturer must submit an application through the CDSCO's SUGAM portal, providing details about the company and the products intended for export.
2. Document Submission: Essential documents include a Free Sale Certificate (FSC) from the country of origin, a Plant Master File (PMF) detailing manufacturing processes, and a Site Master File (SMF) outlining the facility's layout and operations.
3. Fee Payment: The applicant must pay the applicable registration fees, which vary based on the product category and other factors.
4. Technical Review: CDSCO conducts a technical evaluation of the submitted documents to assess the safety, efficacy, and quality of the pharmaceutical products.
5. Inspection: In some cases, CDSCO may require an inspection of the manufacturing facility to verify compliance with Indian standards.
6. Approval: Upon successful evaluation and inspection, CDSCO grants approval, allowing the foreign manufacturer to export pharmaceutical products to India.
The entire process can take several months, depending on the complexity of the product and the completeness of the application. It's crucial for Zimbabwean companies to ensure all documentation is accurate and comprehensive to facilitate a smooth registration process.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure the quality and safety of pharmaceutical products. Manufacturers must provide evidence of GMP compliance, which may include certifications from recognized authorities and detailed descriptions of manufacturing processes. Additionally, CDSCO may conduct inspections to verify adherence to these standards. For plasma products, ensuring the safety and quality of the blood supply is paramount, and manufacturers must demonstrate compliance with relevant health and safety regulations.
To import pharmaceutical products into India, the following documentation is required:
1. Import License (Form 10): Issued by CDSCO, this license authorizes the importation of specific pharmaceutical products.
2. Registration Certificate: A certificate issued by CDSCO confirming that the pharmaceutical product is registered for sale in India.
3. No Objection Certificate (NOC): A certificate from the manufacturer stating that they have no objection to the importation of their product into India.
4. Test License: A license that permits the testing of imported pharmaceutical products to ensure they meet Indian standards.
5. Customs Procedures: Compliance with Indian customs regulations, including proper labeling, packaging, and documentation, is essential for the clearance of pharmaceutical imports.
Ensuring all documentation is accurate and complete is vital to avoid delays or rejections during the import process.
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Zimbabwe to India are exclusively plasma products, indicating a specialized trade relationship. This singular focus suggests that plasma is a critical component in India's pharmaceutical supply chain, possibly due to its use in various medical treatments and therapies. The absence of other pharmaceutical categories in this trade corridor highlights the niche nature of the imports from Zimbabwe.
The importation of plasma products from Zimbabwe to India suggests a focus on specialized and essential medical supplies. While the trade is limited to this category, the consistent demand indicates the importance of these products in the Indian healthcare system. The specialized nature of plasma products underscores the need for high-quality and reliable sources, which Zimbabwe provides.
India's importation of plasma from Zimbabwe is driven by several factors:
1. Quality Requirements: Zimbabwe's adherence to WHO-GMP standards ensures the quality and safety of plasma products, meeting India's stringent regulatory requirements.
2. Supply Consistency: The consistent supply of plasma from Zimbabwe helps India maintain a steady stock of this essential product, crucial for various medical treatments.
3. Regulatory Compliance: Zimbabwe's compliance with international standards facilitates smoother regulatory approvals in India, making it a reliable source for plasma imports.
These factors collectively contribute to the sustained demand for Zimbabwean plasma in the Indian market.
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
1. Most Favored Nation (MFN) Tariff Rates: These rates apply to imports from countries with which India has MFN status, ensuring non-discriminatory treatment.
2. Basic Customs Duty: A duty imposed on imported goods, which varies based on the product category and country of origin.
3. Integrated Goods and Services Tax (IGST): A tax levied on imported goods, applicable to the value of the goods plus customs duty.
4. Health Cess: An additional levy on imported pharmaceutical products, intended to fund health-related initiatives.
The exact rates for these duties and taxes can vary and are subject to periodic revisions by the Indian government.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Zimbabwe concerning pharmaceutical imports. Both countries operate under the World Trade Organization's (WTO) Most Favored Nation (MFN) principle, ensuring non-discriminatory treatment in trade relations. Any future trade agreements or negotiations could potentially alter the current tariff structures and import dynamics.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. This provision can impact the importation of patented pharmaceutical products, as it may limit patentability for certain incremental innovations. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported pharmaceuticals, to ensure affordability and accessibility. These regulations can influence the pricing and market dynamics of imported pharmaceutical products in India.
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
The primary shipping routes for pharmaceutical imports from Zimbabwe to India involve sea freight, with transit times typically ranging from 20 to 30 days, depending on the specific ports of departure and arrival. Air freight options are also available, offering faster transit times of approximately 7 to 10 days. The reliability of these routes is generally high, with established shipping lines and air cargo services facilitating regular shipments. However, factors such as weather conditions, port congestion, and geopolitical events can impact transit times and reliability.
In Zimbabwe, pharmaceutical exports are primarily handled through the port of Beira in Mozambique, which serves as a key gateway for landlocked countries in Southern Africa. In India, major ports handling pharmaceutical imports include Mumbai, Chennai, and Kolkata. These ports are equipped with specialized facilities for handling pharmaceutical products, including cold storage and controlled environments, to maintain product integrity during transit. The infrastructure at these ports supports efficient customs clearance and distribution processes.
India exported pharmaceuticals worth $101.7K to Zimbabwe across 4 verified shipments.
1. NATIONAL BLOOD SERVICE ZIMBABWE — $101.7K. Total: 1 suppliers.
1. YASHRAJ BIOTECHNOLOGY LIMITED — $101.7K. 1 buyers total.
1. Plasma ($101.7K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $101.7K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$25.4K per consignment across 4 shipments.
1 Indian companies. Largest: NATIONAL BLOOD SERVICE ZIMBABWE with $101.7K.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 4 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists